Background/Objectives: Chimeric Antigen Receptor (CAR)-T cell therapy has demonstrated impressive clinical results against hematological malignancies. However, currently commercialized CAR-T therapies are designed for autologous use, which entails some disadvantages, including high costs, manufacturing delays, complex standardization, and frequent production failures due to patient T cell dysfunction. Moreover, their CARs target one specific antigen, increasing the probability of antigen-negative tumor relapses. To overcome these limitations, we developed a novel NKG2D CAR-T cell therapy for allogeneic use with broad target specificity, as this CAR targets eight different ligands commonly upregulated in both solid and hematological tumors. Additionally, the manufacturing process was optimized to improve the phenotypic characteristics of the final product. Methods: Multiplex CRISPR/Cas9 technology was applied to eliminate the expression of TCR and HLA class I complexes in healthy donor T cells to reduce the risk of graft-versus-host disease and immune rejection, respectively, as well as lentiviral transduction for introducing the second-generation NKG2D-CAR. Moreover, we sought to optimize this manufacturing process by comparing the effect of different culture interleukin supplementations (IL-2, IL-7/IL-15 or IL-7/IL-15/IL-21) on the phenotypic and functional characteristics of the product obtained. Results: Our results showed that the novel CAR-T cells effectively targeted cervicouterine and colorectal cancer cells, and that those manufactured with IL-7/IL-15/IL-21 supplementation showed the most suitable characteristics among the conditions tested, considering genetic modification efficiency, cell proliferation, antitumor activity and proportion of the stem cell memory T cell subset, which is associated with enhanced in vivo CAR-T cell survival, expansion and long-term persistence. Conclusions: In summary, this new prototype of NKG2D CAR-T cell therapy for allogeneic use represents a promising universal treatment for a wide range of tumor types.
Acute pancreatitis (AP) patients can be classified into mild or severe outcome based on the presence of organ failure days during hospitalization. However, there are no biomarkers that can predict severity outcome. This study aim is to perform an unbiased characterization of the circulating immunome of AP patients at hospital admission aiming to identify novel biomarkers which could predict disease outcome prior to the onset of organ damage and clinical deterioration. Peripheral blood mononuclear cells (PBMC) were collected from newly hospitalized AP patients. Based on their evolution, patients were classified following the Modified Atlanta classification into mild acute pancreatitis (mAP) ( n = 20) as well as moderately and/or severe acute pancreatitis (ms‐sAP) ( n = 20). PBMC were analysed by high‐dimensional spectral cytometry with unsupervised dimensionality reduction and clustering algorithms based on the subsequent outcome of the patients. Results were further validated by classical gating and functional approaches with a smaller cohort ( n = 8 mAP and n = 8 ms‐sAP). A total of 120 different immune cell clusters were identified and characterized in AP patients at hospitalization. Following computational analysis and classical gating validation approaches, circulating CD2 + CD8 dim NKT‐Like cells were found to be specifically reduced in ms‐sAP patients. Moreover, NKT‐Like cell subsets from these patients displayed an IL‐15 induced expansion of NKG2a and NKp30 referred to mAP. Patients with AP at hospitalization with subsequent ms‐sAP display a specific reduction of NKT‐Like cells coupled with an expanded function. Hence, quantifying the phenotype and/or function of circulating NKT‐Like cells during hospital admission could serve as a predictive biomarker for AP severity, aiding in early stratification and personalized treatment strategies.